US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted A61PA61P35/00
Quick answer
US patent 12421253 (Tetrahydropyridopyrimidine pan-KRas inhibitors) held by Mirati Therapeutics, Inc. expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 29
- CPC classes
- A61P, A61P35/00